Cargando…

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial

IMPORTANCE: Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC). OBJECTIVE: To evaluate efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiele, Elizabeth A., Bebin, E. Martina, Bhathal, Hari, Jansen, Floor E., Kotulska, Katarzyna, Lawson, John A., O'Callaghan, Finbar J., Wong, Michael, Sahebkar, Farhad, Checketts, Daniel, Knappertz, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754080/ https://www.ncbi.nlm.nih.gov/pubmed/33346789 http://dx.doi.org/10.1001/jamaneurol.2020.4607

Ejemplares similares

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial
por: Amin, Sam, et al.
Publicado: (2021)

Add‐on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy
por: Kuchenbuch, Mathieu, et al.
Publicado: (2020)

Secular changes in severity of intellectual disability in tuberous sclerosis complex: A reflection of improved identification and treatment of epileptic spasms?
por: Tye, Charlotte, et al.
Publicado: (2018)

Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program
por: Gaston, Tyler E., et al.
Publicado: (2023)

A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures
por: Brodie, Martin J., et al.
Publicado: (2021)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers
por: Mühlebner, Angelika, et al.
Publicado: (2020)

Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness
por: Kingswood, J Chris, et al.
Publicado: (2019)

Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex
por: Amin, S., et al.
Publicado: (2017)

Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)
por: Sauter, Matthias, et al.
Publicado: (2021)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Seizure Localization in Patients with Multiple Tubers: Presurgical Evaluation in Tuberous Sclerosis
por: Song, Pamela, et al.
Publicado: (2012)

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial
por: Watkins, Paul B., et al.
Publicado: (2020)

A case for cannabidiol in Wolf–Hirschhorn syndrome seizure management
por: Ho, Karen S., et al.
Publicado: (2016)

Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex
por: Sánchez Fernández, Iván, et al.
Publicado: (2020)

Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
por: Nabbout, Rima, et al.
Publicado: (2018)

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?
por: Słowińska, Monika, et al.
Publicado: (2018)

Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
por: Moavero, Romina, et al.
Publicado: (2020)

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
por: Jansen, Anna C., et al.
Publicado: (2019)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study
por: Fan, Heng, et al.
Publicado: (2020)

Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs
por: Garcia, Gabriel A., et al.
Publicado: (2022)

Cannabidiol for functional seizures (psychogenic nonepileptic seizures/attacks) and other stress‐associated disorders
por: Asadi‐Pooya, Ali A.
Publicado: (2023)

Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment
por: Mills, James D., et al.
Publicado: (2017)

Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2020)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
por: Davis, Brittney H., et al.
Publicado: (2021)

Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine
por: Vilela, Luciano Rezende, et al.
Publicado: (2015)

Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence
por: Zavala-Tecuapetla, Cecilia, et al.
Publicado: (2022)

Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial
por: Kotulska, Katarzyna, et al.
Publicado: (2020)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
por: Kingswood, John C., et al.
Publicado: (2017)

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry
por: Marques, Ruben, et al.
Publicado: (2019)

The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
por: Marques, Ruben, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i9l2u9j0mnn8nv67aq5in04cim